Pharmaceutical

Darren Burrell, division lead of corporate risk intelligence at risk analysis company Revolver, and Lisa Anderson, who advises pharma companies on shi...

It’s not uncommon to watch TV and see a pharmaceutical advertisement—even several—that feature a celebrity endorsement. But to really move the needle...

The detailed results from the HARMONi trial—the first global phase 3 data set for the world’s first PD-1xVEGF bispecific, ivonescimab—have sparked a m...

Dive Brief: Novo Nordisk on Wednesday announced plans to lay off about 11% of its workforce as competition for top-selling medicines Ozempic and Wegov...

Today, a brief rundown of news involving Kriya Therapeutics and Odyssey Therapeutics, as well as updates from Amgen, Regeneron and Merck & Co. that yo...

Dive Brief: The Food and Drug Administration on Tuesday approved a drug-device combination for bladder cancer that its developer, Johnson & Johnson, c...

LB Pharmaceuticals raised $285 million in an initial public offering on Wednesday, marking the first sizable new stock offering for a young biotechnol...

Abcuro has appointed George Eldridge as chief financial officer Abcuro has appointed George Eldridge as chief financial officer

Early data reveals strong response rates in ovarian cancer cohort Early data reveals strong response rates in ovarian cancer cohort

Before he brought his talents to the world of healthcare PR and communications, Kareem Clark, Ph.D., was an academic. “I started out as a scientist. B...